Reducing heart disease risk with semaglutide (Wegovy)

For some time, it has been known that obesity is associated with an increased risk of various medical conditions such as heart attacks and strokes. However, a recent study suggests that people using Wegovy have a reduced risk of these conditions by 20 percent. This promising finding stems from a clinical study conducted by the Danish pharmaceutical company Novo Nordisk.

The research, which focused on the medication, involved a total of 17.500 adults aged 45 and older. All participants were either overweight or obese and also had cardiovascular disease. Interestingly, none of them had diabetes or high blood sugar.

According to Novo Nordisk, the study’s findings indicated that participants treated with Wegovy had a 20 percent lower risk of heart attack, stroke, or even death from these causes compared to the group receiving a placebo.

Although the study has not yet undergone formal peer evaluation, Wegovy could potentially become the first medication to significantly enhance the heart health of people with obesity. Martin Holst Lange of Novo Nordisk emphasizes this potential, stating: ‘To date, there are no approved medications for obesity that offer proven effective weight management while simultaneously reducing the risk of heart attacks, strokes, or death from cardiovascular disease.’

Novo Nordisk is hopeful that the outcomes of this study will persuade American and European health authorities to cover the costs of this medication for a large number of patients. “Obesity should be acknowledged as a severe health issue that necessitates decisive treatment,” the company asserts.

Afvallen met GLP-1 medicatie